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Objective: Prostate cancer is the most common noncutaneous cancer among Danish men. 
During the last decade, use of prostate specific antigen (PSA) testing has increased, and in 
clinically localized prostate cancer, curative intended treatment has gained a footing. Our aim 
was to examine possible changes in the short- and long-term survival of patients with prostate 
cancer during 1998–2009.
Study design and setting: From two Danish regions (population, 1.8 million) we included 
all patients (N = 10,547) with an incident diagnosis of prostate cancer retrieved from the Danish 
National Registry of Patients. We determined survival after 1, 3, and 5 years, stratified by age, 
and estimated mortality rate ratios (MRRs) using Cox proportional hazard regression to assess 
changes over time, controlling for age.
Results: During the study period, the annual number of incident prostate cancer patients 
more than doubled, and the median age at diagnosis decreased from 74 to 70 years. The sur-
vival improved over the study period, particularly in the last half of the period (2004–2009). 
Thus, 1-year survival increased from 80% (1998–2000) to 90% (2007–2009), corresponding to 
an age-adjusted MRR of 0.54 (95% confidence interval CI: 0.46–0.63). The expected increase 
in 3- and 5-year survival was even more pronounced: 47%–73% and 34%–60%, respectively. 
This corresponded to a 3-year age-adjusted MRR of 0.46 (95% CI: 0.42–0.51) and a 5-year 
MRR of 0.50 (95% CI: 0.46–0.54). The 1-, 3-, and 5-year overall survival increased in all age 
groups (,70 years, 70–79 years, $80 years).
Conclusion: Survival after prostate cancer has improved in Denmark within the last decade. 
Although diagnosis and treatment improvements could explain this, length and lead time bias 
are likely to have influenced our results.
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Introduction
Clinically significant prostate cancer is a serious condition with a high mortality, which 
in 2009 caused 1216 deaths in Danish men, corresponding to a mortality rate of 20.9 
per 100,000 men per year when standardized to the age distribution of the Danish 
population in the year 2000 (DK-2000).1 With 3900 new cases in 2009, prostate 
cancer has become the far most common cancer among Danish men, with an age-
standardized (DK-2000) incidence rate of 138 per 100,000 men per year.2 During the 
last decades, the incidence of prostate cancer has increased significantly, probably due 
to diagnostic changes, with more widespread use of prostate specific antigen (PSA) 
testing, either on the basis of lower urinary tract symptoms, for example, or as part 
of a general health checkup.3–6 During the period 1998–2005, treatment primarily for Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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patients with clinical localized prostate cancer in Denmark 
has changed. Especially since 2003, these patients more 
frequently have been offered curative intended surgery or 
radiation therapy, instead of being observed until disease 
progression and palliative endocrine treatment was assessed 
as necessary, which was standard before 2003.7 In addition 
to the rising number of curative intended therapies in clini-
cally localized disease, chemotherapy has since 2005 been 
offered systematically to symptomatic castration-resistant 
prostate cancer patients. On top of the introduction of the 
aggressive diagnostic and treatment strategies, the last decade 
has seen major principal changes on a national level in the 
organization of handling prostate cancer. Only 10 years ago, 
prostate cancer patients in Denmark could be treated in surgi-
cal departments without specialized urologists. Since then, 
several smaller hospitals have been merged into larger hos-
pitals, and urology departments have been included in highly 
specialized uro-oncological centers. Despite the introduction 
of curative intended therapy and a life-extending therapy in 
incurable patients, the age-standardized annual death rate 
per 100,000 individuals in Denmark has been completely 
unchanged the last decade.1
The impact of changes in prostate cancer diagnosis, 
setting, and treatments has previously been assessed based 
on Danish registry data from 1985 to 2004.8 We extended 
that study and examined changes in mortality and survival 
in prostate cancer patients within the last decade (1998 to 
2009) by using data from the Danish National Registry of 
Patients (DNRP).
Material and methods
We conducted this study in the central and the northern 
Denmark regions, with a combined population of 1.8 million 
persons. The National Health Service provides tax-supported 
health care for all inhabitants of Denmark, guaranteeing free 
access to hospitals. Virtually no prostate cancer patients were 
treated in private hospitals during the study period.
Identification of prostate  
cancer patients
Through the DNRP, we identified all patients who had a 
first-time hospitalization with prostate cancer in the period 
January 1, 1998 through December 31, 2009. The DNRP 
contains information about all admissions from nonpsy-
chiatric hospitals in Denmark since 1977.9 Outpatient and 
emergency room visits at hospitals have been included since 
1995. This registry includes information on civil registra-
tion number, dates of admission and discharge, surgical 
procedure(s) performed, and up to 20 diagnoses from each 
hospital contact. Diagnoses have been classified according 
to the International Classification of Diseases (ICD) 8th 
edition until the end of 1993 and the 10th edition (ICD-10) 
thereafter. Surgical procedures have been classified according 
to a Danish version of the Nordic Classification of Surgical 
Procedures (NCSP).
The ICD-10 codes used to identify prostate cancer were 
C 61.9.
Survival
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit personal identification number 
to all Danish citizens.10 This number, unique to each Danish 
resident, is used in all Danish registries, allowing unambigu-
ous individual-level data linkage. From the Civil Registration 
System, we obtained information on vital status (dead or 
alive), date of death, and residence for all cancer patients.
Statistical analysis
We followed each patient from date of cancer diagnosis until 
emigration, death, or June 25, 2010, whichever came first. To 
visualize crude survival we constructed Kaplan–Meier curves 
stratified according to the period of diagnosis (1998–2000, 
2001–2003, 2004–2006, and 2007–2009). We estimated 
1-, 3-, and 5-year survival. In the latter periods we estimated 
3- and 5-year survival using a hybrid analysis in which 
survival was estimated using the survival experience of 
patients in the previous periods.11 To compare mortality over 
time we used Cox proportional hazards regression analysis 
with 1998–2000 as the reference period to estimate 1-, 3-, 
and 5-year mortality rate ratios (MRRs) and correspond-
ing 95% confidence intervals (CIs) adjusting for age group 
(,70 years, 70–79 years, $80 years).
Analyses were performed using SAS version 9.2 (SAS 
Institute Inc, Cary, NC).
Results
A total of 10,547 men was diagnosed with prostate cancer 
in the period 1998–2009. The number of patients diagnosed 
increased every year (Table 1). In addition, the median age at 
diagnosis decreased from 74 years in the 1998–2000 period to 
70 years in the 2007–2009 period (Table 1). The age distribu-
tion is shown in Figure 1. In general, survival improved over 
the study period, although the 2004–2006 and the 2007–2009 
periods showed almost similar results (Figure 2). Thus, the 
1-year cumulative survival improved from 80% (1998–2000) 
to 90% (2007–2009). This corresponds to an adjusted MRR Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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of 0.54 (95% CI 0.46–0.63) in 2007–2009, using 1998–2000 
as reference (Table 1). The expected increase in 3- and 
5-year survival was even more pronounced: 47%–73% and 
34%–60%, respectively.
The annual number of diagnosed prostate cancer patients 
more than doubled over the study period, while the median 
age at diagnosis decreased. The annual number of patients 
more than tripled for patients , 70 years. Although most 
pronounced in younger age groups, an increase in annual 
number of incident prostate cancer patients occurred in all 
age groups (Table 2). Among patients 15–69 years of age, 
the 1-year survival increased over the study period from 88% 
to 97%, while the 3- and 5-year survival was expected to 
increase from 60% to 86% and from 48% to 78%, respectively 
(Table 2). Patients in the age groups 70–79 and 80+ years 
had slightly lower survival than patients aged 15–69 years, 
but survival increased in all three age groups over the study 
period (Table 2).
Discussion
In this regional population-based cohort study we found 
that the survival after prostate cancer increased between 
1998 and 2009. This increased survival was present 
across age groups. In addition, the annual number of 
diagnosed prostate cancer patients more than doubled 
over the study period, while the median age at diagnosis 
decreased. Although the national clinical guidelines for 
prostate cancer persistently argue against a formalized 
PSA screening program, PSA measurements are increas-
ingly performed.6
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Figure 1 The age distribution of men diagnosed with prostate cancer in the period 1998–2009 in two of the five Danish regions.
Table 1 The 1-, 3-, and 5-year overall survival and Mrr adjusted for age in the four time periods
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 1684 2120 2962 3781
Median age (years) 74 74 72 70
1 year
Survival 80% (78%–82%) 82% (80%–84%) 89% (88%–90%) 90% (89%–91%)
relative mortality 1(reference) 0.88 (0.76–1.02) 0.51 (0.44–0.60) 0.44 (0.38–0.51)
Adjusted Mrra 1(reference) 0.89 (0.77–1.03) 0.56 (0.48–0.66) 0.54 (0.46–0.63)
3 year
Survival 47% (44%–49%) 59% (56%–61%) 70% (69%–72%) 73% (72%–75%)b
relative mortality 1(reference) 0.73 (0.66–0.80) 0.47 (0.43–0.52) 0.41 (0.37–0.45)b
Adjusted Mrra 1(reference) 0.73 (0.67–0.80) 0.50 (0.46–0.55) 0.46 (0.42–0.51)b
5 year
Survival 34% (31%–36%) 45% (43%–47%) 57% (55%–59%)b 60% (58%–62%)b
relative mortality 1(reference) 0.75 (0.69–0.81) 0.50 (0.46–0.54)b 0.45 (0.41–0.48)b
Adjusted Mrra 1(reference) 0.75 (0.69–0.81) 0.53 (0.49–0.57)b 0.50 (0.46–0.54)b
Notes: Long-term survival is predicted values. aAdjusted for age; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Our study is based on a well defined cohort representing 
approximately one-third of the total Danish male population, 
with nearly complete registration of prostate cancer patients. 
We obtained complete vital status follow-up by using the Civil 
Registry System. Cancer data in Denmark are usually derived 
from the nationwide Danish Cancer Registry because of its 
high completeness and accuracy.12,13 However, until recently 
there has been a substantial delay between the time of data 
submission and availability for outcome monitoring and 
scientific purposes. Therefore, data from the Danish Cancer 
Registry have not been optimal for updated studies of cancer 
survival. Fortunately, data from the DNRP are updated and 
thus facilitates studies that evaluate recent changes. However, 
data from the DNRP might be affected by misclassification 
of prostate cancer diagnoses. Nevertheless, a Danish ovarian 
cancer study used the same data source as in the current study 
and validated the diagnosis codes against those recorded in 
the Danish Cancer Registry.14 The ovarian cancer data proved 
Table 2 The 1-, 3-, and 5-year survival in the four time periods according to three different age groups
Age (years) Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
15–69
  number of cancer patients 565 739 1197 1832
  1-year survival 88% (86%–91%) 90% (87%–92%) 95% (94%–96%) 97% (96%–97%)
  3-year survival 60% (56%–64%) 72% (68%–75%) 84% (81%–86%) 86% (85%–88%)a
  5-year survival 48% (43%–52%) 63% (59%–66%) 75% (72%–77%)a 78% (75%–80%)a
70–79
  number of cancer patients 690 855 1178 1354
  1-year survival 81% (77%–83%) 84% (81%–86%) 89% (87%–91%) 90% (89%–92%)
  3-year survival 48% (44%–52%) 60% (57%–64%) 69% (66%–71%) 71% (68%–73%)a
  5-year survival 34% (30%–37%) 45% (42%–48%) 56% (53%–58%)a 57% (54%–60%)a
80+
  number of cancer patients 429 526 587 595
  1-year survival 67% (62%–71%) 68% (64%–72%) 76% (72%–79%) 72% (68%–76%)
  3-year survival 27% (23%–31%) 37% (33%–41%) 45% (41%–49%) 44% (40%–48%)a
  5-year survival 15% (12%–19%) 18% (15%–22%) 25% (22%–29%)a 24% (21%–28%)a
Note: Long-term survival is predicted values. aPredicted values.
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Figure 2 Overall survival in Danish prostate cancer patients diagnosed in the period 1998–2009 in two of the five Danish regions.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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a completeness of 96% in the hospital discharge registry, with 
a high positive predictive value (87%), and we have no reason 
to expect that the coding of prostate cancer in the DNRP is 
inferior to the coding of ovarian cancer.
The finding of an increasing annual number of incident 
prostate cancers and the decreasing median age at time of 
diagnosis is an expected scenario at a time with a generally 
more aggressive diagnostic strategy. PSA testing has never 
been used more frequently in Denmark than it is today.6 We 
found that survival increased particularly from 2004 to 2009, 
which covers the time period of the curative intended treat-
ment approach in Denmark. Our study thus extends findings 
from a previous study in the exact same geographical area 
which demonstrated an improved prostate cancer survival 
between the years 1985 and 2004.8 In that study, improve-
ment in survival was most markedly observed during the last 
part of the period (2000–2004) and especially in patients 
younger than 70 years of age. Furthermore, the results of 
two nationwide studies presenting Danish prostate cancer 
relative survival estimates corresponding with our study, 
thereby supporting the idea that the general increase in life 
expectancy in the Danish population during the study period 
was not the reason for the observed survival improvement 
in prostate cancer patients.15,16 Traditionally, Denmark has 
been very conservative with respect to the diagnosis and 
treatment of prostate cancer, and starting treatment at a 
very late stage of the disease was recommended until less 
than 15 years ago. This fact is probably a key explanation 
why Danish prostate cancer patients previously have had a 
significantly lower survival rate than prostate cancer patients 
from countries practicing a more aggressive strategy toward 
this disease.17 In the current study, survival increased in 
all age groups. Besides the tremendous curative intended 
treatment effort in younger and clinically localized patients 
during the last decade,7 the phenomenon that survival benefit 
seems independent of patient age at diagnosis could in part 
reflect the introduction of chemotherapy in 2005 intended 
for disseminated disease. Before that there existed no life-
extending treatment in castration-resistant prostate cancer.
The current results should be interpreted cautiously. The 
widespread use of PSA tests will inevitable result in patients 
being diagnosed at earlier disease stage, which automati-
cally leads to patients living longer with a cancer diagnosis 
than previously observed (lead-time bias). Additionally, 
more patients with slowly developing tumors having a 
more favorable prognosis will be diagnosed (length-ime 
bias), some of whom might never become symptomatic 
during the patient’s life (over-diagnosis). The fact that a 
significant portion of prostate cancer patients suffer from 
harmless clinically insignificant disease has been shown 
previously,18 and the risk of over-diagnosis as well as over-
treatment is well documented.18,19 Overall, we find it likely 
that the massive increase in observed survival in prostate 
cancer patients to a greater degree reflects a change in the 
patient population than a real improvement in survival. 
This is also supported by the absence of change in the age 
standardized annual death rate in Denmark during the last 
decade.1 Similarly, the predicted survival should be inter-
preted with caution. Since the predicted values are based 
on the survival observed in previous periods, those will as a 
consequence from the above probably be conservative sur-
vival estimates (under-rating). A limitation of this study is 
the lacking information on disease stage, which would have 
been very informative. Adjusting for stage would probably 
have allowed some degree of separation of screening effects 
from treatment effects. However, quality data of the TNM 
(tumor, lymph node, metastasis) coding were not available 
for the given period of observation.
A previous Danish study based on nationwide registry 
data from the period 1943–1996 found that the incidence 
of prostate cancer increased about 1.6% per year.20 It was 
concluded that the epidemiological pattern of prostate 
cancer incidence seemed to be dominated by changes in 
diagnosis and registration rather than changes in causal 
factors, which supports our speculation concerning the 
current results.
The EUROCARE project was set up in 1989 to measure 
and explain international differences in cancer survival in 
Europe.21 The last EUROCARE report stated that the 5-year 
survival rates for prostate cancer varied significantly more 
than for any other cancer, going from ,40% to .80%. 
EUROCARE thus concluded that the wide range in sur-
vival rates was largely attributable to the differences in the 
intensity of diagnostic and screening activity, especially 
PSA testing.21 This point of view is supported by our study 
and data from Austria, where intensive PSA screening has 
been ongoing since 1992.22 However, the paradigm handling 
prostate cancer has changed during the last 10 years, and 
patients with clinical localized prostate cancer are now 
offered curative treatment. All together, the most likely 
explanation for the steadily increasing incidence and 
survival in Danish prostate cancer patients is identical to 
observations in other Western countries:23 the increased use 
of PSA resulting in identification of earlier and eventually 
clinically insignificant disease, rather than a real improve-
ment in survival.Clinical Epidemiology
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Conclusion
In the last decade (1998–2009) the number of incident 
prostate cancer patients in central and northern Denmark 
increased. At the same time, long-term survival of prostate 
cancer patients has continuously improved significantly. Both 
the rise in incidence and long-term outcome improvement 
was most pronounced in men younger than 70 years of age. 
Although the treatment paradigm has changed significantly 
in the last decade, it seems most likely that the results to a 
greater degree reflect lead and length time bias rather than a 
real improvement in survival.
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